WECHE
Osamu Ohneda(University of Tsukuba), Laurence A. Lasky(Molecular Oncology (United States)), Kinuko Ohneda(Tohoku University), Hisayuki Nomiyama(Kumamoto University), Zhong Zheng(Tsinghua University), Takeshi Miyamoto(Kumamoto Health Science University), Steven Gold(Sepragen Corporation (United States)), Toshio Suda(Chinese Academy of Sciences), Richard McIndoe(Sepragen Corporation (United States)), Bruce E. Taillon(Sepragen Corporation (United States)), David A. Lewin(Sepragen Corporation (United States)), Fumio Arai(Kyushu University), Richard A. Shimkets(Howard Hughes Medical Institute)
Cited by 39
Related Papers
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
|Proceedings of the National Academy of Sciences|1998|4.3k
Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion
|Cell|1997|1.5k
Liddle's syndrome: Heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel
|Cell|1994|1.3k
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i><sup>1</sup>
|Endocrinology|1998|1.2k
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
|The Journal of Experimental Medicine|2005|899